A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Healthy Aging and Longevity: A Delivery Problem First

Most longevity compounds fail at the gut wall before they reach the biology they target. NAD+ precursors, urolithin A, spermidine and senolytic flavonoids all show clear effects in animal models, and far thinner or mixed evidence in people. Vegalab works on the delivery side of that gap: getting a defined dose of a fragile or poorly absorbed molecule to the tissue.

What aging biology actually covers

Researchers now describe aging through 12 hallmarks, including genomic instability, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence and chronic low-grade inflammation. Each hallmark maps to measurable pathways (NAD+ levels, mTOR and AMPK signaling, mitophagy, senescent cell burden). No regulator in the US, EU or Canada recognizes aging itself as a treatable indication, so products in this space are positioned as supplements, natural health products or cosmetics, and their claims must stay within structure and function or ingredient-level language. Drug development targets specific age-related diseases instead.

Where the evidence stands

Evidence tiers vary sharply. Rapamycin extended lifespan in genetically heterogeneous mice even when started late in life, but it is an immunosuppressant approved for transplant use, not for aging. NMN raised muscle insulin sensitivity in one small trial in prediabetic women. Urolithin A improved some mitochondrial gene expression markers in older adults. Spermidine and fisetin effects rest largely on animal data. A partner building in this category needs an honest evidence map per compound, and a formulation that makes the human trial worth running.

Delivery constraints across the category

The recurring problems are predictable. NMN and NR are water soluble but unstable in solution and partly converted to nicotinamide before reaching tissue. Fisetin, quercetin, resveratrol and CoQ10 are poorly water soluble, so absorption depends on dissolution. Glutathione and NAD+ are broken down in the gut. Several compounds oxidize on shelf. These are the variables a delivery system can change; see the Delivery Challenges library and the Compound Library for each molecule.

How partners use this page

Use the Health Areas column to scope a product concept, then move to the compound pages for molecular data and regulatory status, and to Routes of Delivery to choose a format. Feasibility studies start from a defined active, target market and route. A typical first brief names the compound, the intended market (US supplement, Canadian NHP, EU food supplement or cosmetic), the preferred format and the claim ceiling that market allows. From there, Vegalab designs stability and dissolution work before any clinical step.

Key facts

How our delivery technology applies

Longevity actives fall into two delivery groups. Hydrophilic, unstable molecules (NMN, NR, glutathione) need protection from hydrolysis, oxidation and gut enzymes; a multi-layer biopolymer shell limits water and oxygen contact on shelf and slows release in the upper gut. Lipophilic polyphenols and quinones (fisetin, resveratrol, CoQ10) need dispersion; encapsulation in a nano-scale carrier raises surface area and holds the molecule in a dispersed state. Both are formulation hypotheses tested in feasibility studies, not proven outcomes.

Scope a longevity formulation with our team: request a feasibility call.

Related reading

Last updated: